Magazine Article | January 9, 2018

Can Joseph Papa Save Valeant?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

There’s no doubt about it — Joseph Papa took a huge risk and may have made a huge mistake. At the pinnacle of a firestorm of negative headlines and government investigations into Valeant Pharmaceuticals, Papa decided to take the helm of the embattled company, leaving behind a nearly 10-year successful career as chairman and CEO of OTC and generics drugmaker Perrigo.

It’s a story that has been quietly unfolding since Papa succeeded Michael Pearson in May 2016. But a little quiet is something this company likely relishes these days. For now, free of the media’s spotlight, Papa and his staff can continue with what he refers to as “the turnaround opportunity of a lifetime.”

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: